{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:18:19Z","timestamp":1768292299019,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early-stage lung cancer, primarily treated with surgery, often occur in poor surgical candidates (impaired respiratory function, prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-invasive alternative that provides comparable local control. This technique is particularly relevant for surgically resectable metachronous lung cancer, in patients unable to undergo surgery.. The objective of this study is to evaluate the clinical outcome of patients treated with SABR for stage I metachronous lung cancer (MLC) versus stage I primary lung cancer (PLC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>137 patients treated with SABR for stage I non-small cell lung cancer were retrospectively reviewed, of which 28 (20.4%) were MLC and 109 (79.6%) were PLC. Cohorts were evaluated for differences in overall survival (OS), progression-free survival (PFS), metastasis-free survival, local control (LC), and toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After SABR, patients treated for MLC have comparable median age (76.6 vs 78.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.2), 3-year LC (83.6% vs. 72.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.2), PFS (68.7% vs. 50.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.9), and OS (78.6% vs. 52.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.9) as PLC, along with similar rates of total (54.1% vs. 42.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.6) and grade 3\u2009+\u2009toxicity (3.7% vs. 3.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.9). Previous treatment of MLC patients was either surgery (21\/28, 75%) or SABR (7\/28, 25%). The median follow-up was 53\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SABR is a safe and effective approach for localized metachronous lung cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02286-5","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:03:24Z","timestamp":1686143004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Jonathan","family":"Benzaquen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Bondiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiane","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Hugo","family":"Marquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Berthet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash O.","family":"Naghavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Schiappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Doyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2286_CR1","unstructured":"Inca. Les cancers en France l\u2019essentiel des faits et chiffres. E-CancerFr 2019."},{"key":"2286_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.ejso.2021.01.002","volume":"47","author":"GG Akhtar-Danseh","year":"2021","unstructured":"Akhtar-Danseh GG, Akhtar-Danesh N, Finley C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur J Surg Oncol. 2021;47:1791\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"2286_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/thx.2003.018044","volume":"59","author":"MLG Janssen-Heijnen","year":"2004","unstructured":"Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, Smeenk FWJM, Van Geffen HJAA, Coebergh JWW. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004;59:602\u20137.","journal-title":"Thorax"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2016.70.4718","volume":"35","author":"CSH Ng","year":"2017","unstructured":"Ng CSH, Zhao ZR, Lau RWH. Tailored therapy for stage I non-small-cell lung cancer. J Clin Oncol. 2017;35:268\u201370.","journal-title":"J Clin Oncol"},{"key":"2286_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/02656736.2018.1434901","volume":"34","author":"W Yao","year":"2018","unstructured":"Yao W, Lu M, Fan W, Huang J, Gu Y, Gao F, et al. Comparison between microwave ablation and lobectomy for stage I non-small cell lung cancer: a propensity score analysis. Int J Hyperth. 2018;34:1329\u201336.","journal-title":"Int J Hyperth"},{"key":"2286_CR6","doi-asserted-by":"publisher","first-page":"e0209002","DOI":"10.1371\/journal.pone.0209002","volume":"13","author":"ZG Hu","year":"2018","unstructured":"Hu ZG, Li WX, Ruan YS, Zeng FJ. Incidence trends and risk prediction nomogram of metachronous second primary lung cancer in lung cancer survivors. PLoS ONE. 2018;13:e0209002.","journal-title":"PLoS ONE"},{"key":"2286_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tranon.2017.02.009","volume":"10","author":"J Saab","year":"2017","unstructured":"Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H. Utility of genomic analysis in differentiating synchronous and metachronous lung adenocarcinomas from primary adenocarcinomas with intrapulmonary metastasis. Transl Oncol. 2017;10:442\u20139.","journal-title":"Transl Oncol"},{"key":"2286_CR8","doi-asserted-by":"publisher","first-page":"10361","DOI":"10.2147\/CMAR.S268081","volume":"12","author":"L Zhao","year":"2020","unstructured":"Zhao L, Liu C, Xie G, Wu F, Hu C. Multiple primary lung cancers: a new challenge in the era of precision medicine. Cancer Manag Res. 2020;12:10361\u201375.","journal-title":"Cancer Manag Res"},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1\u201321.","journal-title":"Ann Oncol"},{"key":"2286_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.ijrobp.2016.04.016","volume":"95","author":"N Bi","year":"2016","unstructured":"Bi N, Shedden K, Zheng X, Kong FMS. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage I non-small cell lung cancer: a systemic review and pooled analysis. Int J Radiat Oncol Biol Phys. 2016;95:1378\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2013.09.006","volume":"109","author":"F Sold\u00e0","year":"2013","unstructured":"Sold\u00e0 F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1\u20137.","journal-title":"Radiother Oncol"},{"key":"2286_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.radonc.2011.12.005","volume":"104","author":"KM Creach","year":"2012","unstructured":"Creach KM, Bradley JD, Mahasittiwat P, Robinson CG. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104:19\u201322.","journal-title":"Radiother Oncol"},{"key":"2286_CR13","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/cncr.28217","volume":"119","author":"JY Chang","year":"2013","unstructured":"Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013;119:3402\u201310.","journal-title":"Cancer"},{"key":"2286_CR14","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.cllc.2014.12.011","volume":"16","author":"T Shintani","year":"2015","unstructured":"Shintani T, Masago K, Takayama K, Ueki K, Kimino G, Ueki N, et al. Stereotactic body radiotherapy for synchronous primary lung cancer: clinical outcome of 18 cases. Clin Lung Cancer. 2015;16:e91\u20136.","journal-title":"Clin Lung Cancer"},{"key":"2286_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.radonc.2013.04.026","volume":"107","author":"GHMJ Griffioen","year":"2013","unstructured":"Griffioen GHMJ, Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol. 2013;107:403\u20138.","journal-title":"Radiother Oncol"},{"key":"2286_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13014-015-0340-9","volume":"10","author":"D Owen","year":"2015","unstructured":"Owen D, Olivier KR, Mayo CS, Miller RC, Nelson K, Bauer H, et al. Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol. 2015;10:43.","journal-title":"Radiat Oncol"},{"key":"2286_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1754-9485.2012.02393.x","volume":"56","author":"C Matthiesen","year":"2012","unstructured":"Matthiesen C, Thompson JS, De La Fuente HT, Ahmad S, Herman T. Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer. J Med Imaging Radiat Oncol. 2012;56:561\u20136.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2286_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cllc.2018.10.010","volume":"20","author":"J Nikitas","year":"2019","unstructured":"Nikitas J, DeWees T, Rehman S, Abraham C, Bradley J, Robinson C, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers. Clin Lung Cancer. 2019;20:107\u201316.","journal-title":"Clin Lung Cancer"},{"key":"2286_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijrobp.2020.02.001","volume":"107","author":"Z Ayoub","year":"2020","unstructured":"Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, et al. Definitive management of presumed synchronous early stage non-small cell lung cancers: outcomes and utility of stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2020;107:261\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2286_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3322\/caac.21390","volume":"67","author":"R Rami-Porta","year":"2017","unstructured":"Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:138\u201355.","journal-title":"CA Cancer J Clin"},{"key":"2286_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0022-5223(19)40289-4","volume":"70","author":"N Martini","year":"1975","unstructured":"Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606\u201312.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2286_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0003-4975(95)00067-U","volume":"59","author":"T Antakli","year":"1995","unstructured":"Antakli T, Schaefer RF, Rutherford JE, Read RC. Second primary lung cancer. Ann Thorac Surg. 1995;59:863\u20137.","journal-title":"Ann Thorac Surg"},{"key":"2286_CR23","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","volume":"37","author":"SH Benedict","year":"2010","unstructured":"Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078\u2013101.","journal-title":"Med Phys"},{"key":"2286_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00151","author":"A Chi","year":"2014","unstructured":"Chi A, Nguyen NP, Komaki R. The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Front Oncol. 2014. https:\/\/doi.org\/10.3389\/fonc.2014.00151.","journal-title":"Front Oncol"},{"key":"2286_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2286_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/JTO.0000000000000576","volume":"10","author":"NE Verstegen","year":"2015","unstructured":"Verstegen NE, Lagerwaard FJ, Hashemi SMS, Dahele M, Slotman BJ, Senan S. Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer. J Thorac Oncol. 2015;10:1195\u2013200.","journal-title":"J Thorac Oncol"},{"key":"2286_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12893-019-0643-0","volume":"19","author":"TF Chen","year":"2019","unstructured":"Chen TF, Xie CY, Rao BY, Shan SC, Zhang X, Zeng B, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg. 2019;19:185.","journal-title":"BMC Surg"},{"key":"2286_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","volume":"7","author":"GMM Videtic","year":"2017","unstructured":"Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7:295\u2013301.","journal-title":"Pract Radiat Oncol"},{"key":"2286_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.lungcan.2014.12.013","volume":"87","author":"L Jiang","year":"2015","unstructured":"Jiang L, He J, Shi X, Shen J, Liang W, Yang C, et al. Prognosis of synchronous and metachronous multiple primary lung cancers: Systematic review and meta-analysis. Lung Cancer. 2015;87:303\u201310.","journal-title":"Lung Cancer"},{"key":"2286_CR30","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1177\/0300060513504707","volume":"41","author":"X Xue","year":"2013","unstructured":"Xue X, Liu Y, Pan L, Wang Y, Wang K, Zhang M, et al. Diagnosis of multiple primary lung cancer: a systematic review. J Int Med Res. 2013;41:1779\u201387.","journal-title":"J Int Med Res"},{"key":"2286_CR31","doi-asserted-by":"publisher","first-page":"S523","DOI":"10.21037\/jtd.2019.01.56","volume":"11","author":"C Chen","year":"2019","unstructured":"Chen C, Huang X, Peng M, Liu W, Yu F, Wang X. Multiple primary lung cancer: a rising challenge. J Thorac Dis. 2019;11:S523\u201336.","journal-title":"J Thorac Dis"},{"key":"2286_CR32","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1378\/chest.07-1860","volume":"132","author":"WM Alberts","year":"2007","unstructured":"Alberts WM. Diagnosis and management of lung cancer executive summary. Chest. 2007;132:1S-19S.","journal-title":"Chest"},{"key":"2286_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2014.02.014","volume":"85","author":"A Fonseca","year":"2014","unstructured":"Fonseca A, Detterbeck FC. How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules. Lung Cancer. 2014;85:7\u201311.","journal-title":"Lung Cancer"},{"key":"2286_CR34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jtho.2021.03.018","volume":"16","author":"D Goodwin","year":"2021","unstructured":"Goodwin D, Rathi V, Conron M, Wright GM. Genomic and clinical significance of multiple primary lung cancers as determined by next-generation sequencing. J Thorac Oncol. 2021;16:1166\u201375.","journal-title":"J Thorac Oncol"},{"key":"2286_CR35","first-page":"3103","volume":"35","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Masago K, Kato R, Otsuka K, Okuda C, Hata A, et al. A new strategy for metachronous primary lung cancer stereotactic body radiation therapy with concurrent chemotherapy. Anticancer Res. 2015;35:3103\u20138.","journal-title":"Anticancer Res"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02286-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02286-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:04:48Z","timestamp":1686143088000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02286-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02286-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In compliance with the declaration of Helsinki, the present study was approved by the French National Health Authorities (registration number: MR 004\u2014n\u00b0 F20210825142518). All families received written information on the study and gave their consent to the anonymous use of patients\u2019 data for research purposes. A signed free and informed consent was collected before administration of the SABR treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests relating to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"97"}}